๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Zhengzhou
Clinical trial register · China

Clinical Trials in Zhengzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Zhengzhou 72 Henan 4 Luoyang 2 Anyang 1 Xinxiang 1
Narrow the registerReset
Recruitment status
Phase
Site location
Zhengzhou72 Henan4 Luoyang2 Anyang1 Xinxiang1
All 6 locations
Target enrolment
to

Trials with a site in Zhengzhou

72 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma
NCT07459608Indolent Lymphoma, WM, MZL, CLL / SLL
Henan Cancer Hospital
Phase 2
75
Zhengzhou
2026-07-10
Not yet open
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
NCT07684950Mantle Cell Lymphoma (MCL)
Henan Cancer Hospital
Phase 2
45
Zhengzhou
2026-06-30
Recruiting
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
NCT07629817Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
Phase 3
1,044
Zhengzhou
2026-06-16
Not yet open
Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer
NCT07610629Gastric Adenocarcinoma
Henan Cancer Hospital
Phase 2
50
Zhengzhou
2026-05-05
Not yet open
Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
NCT07472621DLBCL - Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Observational
20
Zhengzhou
2026-03-10
Recruiting
A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer
NCT07540533Advanced Breast Cancer
Henan Cancer Hospital
Phase 2
92
Zhengzhou
2026-01-20
Recruiting
Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
NCT07233720Marginal Zone Lymphoma
Henan Cancer Hospital
Observational
30
Zhengzhou
2025-11-18
Not yet open
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
NCT07125950Advanced Breast Cancer
Henan Cancer Hospital
Phase 2
60
Zhengzhou
2025-09-30
Recruiting
Exploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Meningeal Metastasis of Lung Cancer
NCT07559097Leptomeningeal Metastasis From Lung Cancer
Henan Cancer Hospital
Phase 1/2
14
Zhengzhou
2025-09-08
Recruiting
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
NCT06967103Breast Cancer, HR+/HER2- Breast Cancer
Henan Cancer Hospital
Phase 2
238
Zhengzhou
2025-09-08
Not yet open
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
NCT07136974Breast Cancer, HER2 + Breast Cancer
Henan Cancer Hospital
Phase 2
280
Zhengzhou
2025-09-01
Recruiting
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
NCT07100600HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy
Henan Cancer Hospital
Phase 2
224
Zhengzhou
2025-08-30
Recruiting
Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001
NCT07264569Meningeal Metastasis
Henan Cancer Hospital
Phase 1/2
42
Zhengzhou
2025-06-25
Recruiting
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
NCT07057427Breast Cancer
Henan Cancer Hospital
Phase 3
812
Zhengzhou
2025-06-24
Not yet open
Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors
NCT06955390Solid Tumors
Henan Cancer Hospital
Phase 1/2
32
Zhengzhou
2025-05-01
Not yet open
The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer
NCT06934733Advanced or Metastatic Breast Cancer
Henan Cancer Hospital
Not applicable
124
Zhengzhou
2025-05
Recruiting
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
NCT06927180Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Henan Cancer Hospital
Phase 2
180
Zhengzhou
2025-04-16
Recruiting
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
NCT06860529HR+/HER2- Breast Cancer
Henan Cancer Hospital
Phase 2
357
Zhengzhou
2025-04-15
Not yet open
Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
NCT06897917Opioid-Induced Constipation, Pain Cancer
Henan Cancer Hospital
Phase 4
203
Zhengzhou
2025-04
Recruiting
Organoid-guided Personalized Treatment of Pleural Effusion
NCT06959173Lung Cancer
Henan Cancer Hospital
Observational
20
Zhengzhou
2025-02-21
Recruiting
Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC
NCT07244016Extensive-stage Small-cell Lung Cancer
Henan Cancer Hospital
Observational
40
Zhengzhou
2025-02-20
Not yet open
Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure
NCT06786208Non Small Cell Lung Cancer
Henan Cancer Hospital
Observational
55
Zhengzhou
2025-02-01
Not yet open
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
NCT06793228SCLC, Extensive Stage
Henan Cancer Hospital
Phase 2
250
Luoyang, Xinxiang, Zhengzhou
2025-01-15
Recruiting
Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
NCT07187908Primary/Secondary Prevention, High Risk for Febrile Neutropenia of Chemotherapy Regimens, Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia
Henan Cancer Hospital
Phase 2
1,076
Zhengzhou
2025-01-01
Not yet open
Application of LARS Ligament in Bone Prosthesis Replacement
NCT05616182Malignant Tumor
Henan Cancer Hospital
Observational
100
Zhengzhou
2024-12-30
Not yet open
Application of 3D Printed Prosthesis in Limb Salvage Surgery for Bone Tumors
NCT05616195Malignant Tumor
Henan Cancer Hospital
Observational
80
Zhengzhou
2024-12-28
Not yet open
Application of Antiosteoporosis Therapy in Osteolysis
NCT05617846Limb; Fusion, Complication
Henan Cancer Hospital
Observational
100
Zhengzhou
2024-12-28
Recruiting
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
NCT06643000Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation
Henan Cancer Hospital
Not applicable
60
Zhengzhou
2024-12-20
Recruiting
NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
NCT06781281Breast Cancer Invasive
Henan Cancer Hospital
Observational
709
Zhengzhou
2024-12-04
Recruiting
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
NCT06817525Triple-negative Breast Cancer
Henan Cancer Hospital
Phase 2
64
Zhengzhou
2024-11-06
Not yet open
Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study
NCT06685354Hepatocellular Carcinoma (HCC)
Henan Cancer Hospital
Phase 2
11
Zhengzhou
2024-11
Not yet open
RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors
NCT06545201KRAS G12V, T Cell Therapy
Henan Cancer Hospital
Phase 1
30
Zhengzhou
2024-08-01
Not yet open
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
NCT06554028Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms
Henan Cancer Hospital
Phase 2
46
Zhengzhou
2024-08
Not yet open
Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC
NCT06465238NSCLC
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2024-06
By invitation
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
NCT06370416Non-small Cell Lung Cancer
Henan Cancer Hospital
Phase 2
41
Zhengzhou
2024-04-02
Recruiting
Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma
NCT06749730Unresectable Biliary Tract Carcinoma
Henan Cancer Hospital
Phase 2
63
Zhengzhou
2024-04-01
Recruiting
RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors
NCT06546150KRAS G12D, T Cell Therapy
Henan Cancer Hospital
Phase 1
30
Zhengzhou
2024-03-01
Recruiting
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer
NCT06329973Metastatic Gastroesophageal Junction Adenocarcinoma
Henan Cancer Hospital
Phase 1/2
70
Zhengzhou
2024-02-28
Recruiting
TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer
NCT06293014Colorectal Cancer
Henan Cancer Hospital
Phase 2
224
Zhengzhou
2024-02-23
Recruiting
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
NCT07334431Gastric Adenocarcinoma, Gastric (Stomach) Cancer, GEJ Adenocarcinoma, HER2-positive Gastric Cancer
Henan Cancer Hospital
Phase 1/2
45
Zhengzhou
2024-02-22
Not yet open
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
NCT06236997Small Cell Lung Carcinoma
Henan Cancer Hospital
Phase 2
48
Zhengzhou, Wuhan
2024-02-10
Recruiting
Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib
NCT06478927Hepatocellular Carcinoma
Henan Cancer Hospital
Not applicable
22
Zhengzhou
2024-01-15
Recruiting
Evaluating Safety ,Tolerability, Pharmacokinetic,Efficacy of WJ01024 or WJ01024 Combined With Ruxolitinib in Patients With Myelofibrosis
NCT07802405MF With Splenomegaly
Henan Cancer Hospital
Phase 1
20
Zhengzhou
2023-11-21
Recruiting
A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
NCT06774222Gastric/Gastroesophageal Junction Adenocarcinoma
Henan Cancer Hospital
Phase 2
69
Zhengzhou
2023-09-12
Recruiting
The Maintenance Treatment of "ITIVA" in AML Patients
NCT06256627Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease, Interferon-ฮฑ-1b
Henan Cancer Hospital
Not applicable
130
Zhengzhou
2023-07-11
Recruiting
A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
NCT05911958HER2 Low Breast Carcinoma
Henan Cancer Hospital
Phase 2
66
Zhengzhou
2023-07-05
Recruiting
Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors
NCT05596344Malignant Tumor, Anxiety, Depression
Henan Cancer Hospital
Observational
200
Zhengzhou
2023-05-20
Recruiting
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
NCT05918328Breast Cancer, HER2-positive Breast Cancer
Henan Cancer Hospital
Phase 2
610
Zhengzhou
2023-05-03
Recruiting
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
NCT05617859Effectiveness, Sexuality
Henan Cancer Hospital
Phase 2
60
Zhengzhou
2023-04-30
Recruiting
To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients
NCT06605521Locally Advanced Breast Cancer
Henan Cancer Hospital
Observational
300
Zhengzhou
2023-04-04
Recruiting
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
NCT05769010Metastatic Breast Cancer
Henan Cancer Hospital
Phase 2
150
Zhengzhou
2023-03-31
Recruiting
Utidelone Combined With Bevacizumab in the Treatment of โ‰ฅ 2 Lines of HER-2 Negative Advanced Breast Cancer
NCT05398861HER-2 Negative Breast Cancer
Henan Cancer Hospital
Phase 2
79
Zhengzhou
2022-08-19
Recruiting
Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors
NCT05468970Bone and Soft Tissue Tumors, Clinical Features
Henan Cancer Hospital
Observational
6,000
Zhengzhou
2022-08-03
Recruiting
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT05495152Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
Phase 3
219
Zhengzhou
2022-08-01
Recruiting
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
NCT05377658Non-small Cell Lung Cancer
Henan Cancer Hospital
Phase 2
43
Zhengzhou
2022-07-26
Active, closed
Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer
NCT05177068Gastric Cancer
Henan Cancer Hospital
Phase 2
42
Zhengzhou
2022-05-13
Recruiting
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
NCT05209620Central Nervous System Lymphoma
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2021-12-21
Recruiting
Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer
NCT05063136Breast Cancer
Henan Cancer Hospital
Phase 3
1,979
Zhengzhou
2021-09-28
Recruiting
Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
NCT04891016Chemotherapy, Immune Checkpoint Inhibitor, Locally Advanced Gastric Carcinoma
Henan Cancer Hospital
Phase 2
60
Zhengzhou
2021-06-25
Recruiting
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
NCT04737889Primary Central Nervous System Lymphoma
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2021-01-13
Recruiting
A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
NCT04547907Breast Cancer,HER2-positive
Henan Cancer Hospital
Phase 3
688
Zhengzhou
2020-09-18
Recruiting
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
NCT04280822Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
Henan Cancer Hospital
Phase 3
400
Zhengzhou
2020-04-21
Recruiting
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
NCT04138212Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
Phase 3
456
Zhengzhou
2019-10-22
Active, closed
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
NCT04067037Classical Hodgkin Lymphoma
Henan Cancer Hospital
Phase 2
60
Anyang, Luoyang, Zhengzhou
2019-08-26
Recruiting
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
NCT04263935Lymphoma, Gene Abnormality
Henan Cancer Hospital
Observational
200
Zhengzhou
2019-01-03
Rows per page Showing 1–72 of 72
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhengzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 72 of those studies with a site in Zhengzhou that also match the filters currently applied.

How many clinical trials are recruiting in Zhengzhou?

47 of the 72 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 20 have not yet opened recruitment, 4 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhengzhou), 72 studies
PhaseStudiesRecruitingShare
Phase 2382252.8%
Observational13818.1%
Phase 3779.7%
Not applicable546.9%
Phase 1/2546.9%
Phase 1324.2%
Phase 4101.4%

Most active sponsors

Lead sponsors with the most studies (Zhengzhou)
Lead sponsorStudiesRecruiting
Henan Cancer Hospital7247
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.